313 related articles for article (PubMed ID: 26867157)
21. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
22. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
24. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
25. Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.
Rosati G; Bilancia D; Germano D; Dinota A; Romano R; Reggiardo G; Manzione L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi128-32. PubMed ID: 17591806
[TBL] [Abstract][Full Text] [Related]
26. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
27. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Yi JH; Lee J; Lee J; Park SH; Park JO; Yim DS; Park YS; Lim HY; Kang WK
Br J Cancer; 2012 Apr; 106(9):1469-74. PubMed ID: 22460270
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
[TBL] [Abstract][Full Text] [Related]
29. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
[TBL] [Abstract][Full Text] [Related]
30. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Ford HE; Marshall A; Bridgewater JA; Janowitz T; Coxon FY; Wadsley J; Mansoor W; Fyfe D; Madhusudan S; Middleton GW; Swinson D; Falk S; Chau I; Cunningham D; Kareclas P; Cook N; Blazeby JM; Dunn JA;
Lancet Oncol; 2014 Jan; 15(1):78-86. PubMed ID: 24332238
[TBL] [Abstract][Full Text] [Related]
32. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Rao S; Starling N; Cunningham D; Benson M; Wotherspoon A; Lüpfert C; Kurek R; Oates J; Baselga J; Hill A
Br J Cancer; 2008 Sep; 99(6):868-74. PubMed ID: 19238629
[TBL] [Abstract][Full Text] [Related]
35. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
[TBL] [Abstract][Full Text] [Related]
36. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A
Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H; Ryu MH; Kim KP; Ryoo BY; Park SR; Kim BS; Lee IS; Kim HS; Yoo MW; Yook JH; Oh ST; Kim BS; Kang YK
Gastric Cancer; 2017 Nov; 20(6):970-977. PubMed ID: 28303362
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
Sym SJ; Chang HM; Ryu MH; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Ann Surg Oncol; 2010 Apr; 17(4):1024-32. PubMed ID: 19941081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
